Exercise News and Research

Latest Exercise News and Research

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

Exercise alone without creatine supplements helps in cardiac rehabilitation

Athletes have been enjoying the benefits of creatine supplements to gain stronger muscles since the 1990s, and the supplement has also proven beneficial among other groups. Could it help cardiac patients regain strength to help with their heart-training workouts as part of rehabilitation? The evidence at this stage suggests not - exercise alone proved a far more powerful tonic for patients in a study out today. The results appear in the journal Clinical Rehabilitation, published by SAGE.

23 Jun 2010

Nature Rocks, American Heart Association encourage increased physical activity among all Americans

Today Nature Rocks, a national program created to inspire and empower parents to take their families to play, explore and enjoy quality time in nature, announced a collaboration with the American Heart Association's Start! Initiative. Start! encourages increased physical activity among all Americans, emphasizing walking because it's easy, free and has the lowest dropout rate of any form of activity.

22 Jun 2010

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics Inc. and sanofi-aventis announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years.

22 Jun 2010

Report says G8 countries short $10B on $50B commitment, reveals mixed progress on health goals

An accountability report, prepared by officials in G8 member countries' foreign affairs departments, acknowledges that G8 "countries are $10 billion behind the five-year, $50-billion commitment they made at their 2005 summit in Scotland," the Canadian Press/CTV News reports (6/20).

22 Jun 2010

Lack of tracking of medical devices' performance raises questions about safety and efficacy

"Amid the booming use of artificial joints in the United States, the breakup between Dr. Berger and Zimmer highlights what experts say is a troubling situation for patients and doctors: when disputes arise about orthopedic implant safety, there are no independent referees or sources of information because no one tracks the performance of the devices.

22 Jun 2010

Cadence Pharmaceuticals to acquire Incline Therapeutics

Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.

22 Jun 2010

Angeion launches new TRUcal resting metabolic rate system

Angeion Corporation announced that it has launched its new TRUcal™ resting metabolic rate system. Part of its New Leaf® product line, TRUcal includes an analyzer that gently measures one's breath for oxygen and carbon dioxide which gives consumers their true individualized daily calories their body requires. The TRUcal™ system also includes a compact netbook with Bluetooth® technology, adding the benefit of wireless connectivity.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

Aradigm announces $5 million private placement

Aradigm Corporation today announced that it has entered into a definitive agreement for the sale of common stock and warrants to three existing shareholders and one new investor in a private placement for aggregate gross proceeds of approximately $5 million. The closing of the private placement is subject to the satisfaction of customary closing conditions.

21 Jun 2010

Too much tea raises the risk of rheumatoid arthritis: Study

Rheumatoid arthritis (RA) a severely debilitating inflammatory disease of the joints is on the rise worldwide. It leads to severe pain, stiffness, swelling and loss of movement of joints like knees, wrist and even fingers. RA affects women more than men. RA occurs in people who develop a rogue immune system that attacks the tissue that lines the joint cavities called the synovium leading to degeneration of the joints and the symptoms of the disease. In 1995 36.4 per 100,000 women were diagnosed with RA whereas in 2005 the number rose to 54 per 100,000 women.

20 Jun 2010

NLRB issues third strike against Sal Rosselli, other former SEIU-UHW officials

The National Labor Relations Board issued a third strike against Sal Rosselli, ousted president of the Service Employees International Union - United Healthcare Workers West (SEIU-UHW), and other former union officials who formed the National Union of Healthcare Workers (NUHW) after they were removed from office.

19 Jun 2010

Justice Department files stipulated settlement agreement resolving portion of lawsuit against Erie County

The Justice Department today announced that it has filed a stipulated settlement agreement resolving a portion of its lawsuit against Erie County, N.Y., regarding the limited issue of suicide prevention and related mental health care.

19 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.

19 Jun 2010

BioTime announces warrant discount offer

BioTime, Inc. announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share.

19 Jun 2010

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Tongjitang Chinese Medicines Company, a leading specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China, today announced its financial results for the quarter ended March 31, 2010.

19 Jun 2010

Physical fitness reduces metabolic risk in college students

Staying in shape may bolster the metabolic profiles of college students, even in those with higher than desirable body fat percentages. In an epidemiological study, researchers at the Friedman School of Nutrition Science and Policy at Tufts University found an association between physical fitness, body fat percentage and certain metabolic risk factors that are precursors to cardiovascular disease and Type 2 diabetes.

18 Jun 2010

Research examines relationship between body-image distortion and weight-loss behaviors

Normal weight and underweight teenage girls who falsely believe they are overweight are at significantly greater risk of succumbing to unnecessary and unsafe weight-loss behaviors than girls who can accurately assess their weight status, according to new research by a University of Illinois expert in eating disorders and body-image perception.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Exercise News and Research

Latest Exercise News and Research

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Exercise alone without creatine supplements helps in cardiac rehabilitation

Nature Rocks, American Heart Association encourage increased physical activity among all Americans

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Report says G8 countries short $10B on $50B commitment, reveals mixed progress on health goals

Lack of tracking of medical devices' performance raises questions about safety and efficacy

Cadence Pharmaceuticals to acquire Incline Therapeutics

Angeion launches new TRUcal resting metabolic rate system

BioSante announces $15 million registered direct offering

Aradigm announces $5 million private placement

Too much tea raises the risk of rheumatoid arthritis: Study

NLRB issues third strike against Sal Rosselli, other former SEIU-UHW officials

Justice Department files stipulated settlement agreement resolving portion of lawsuit against Erie County

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

BioTime announces warrant discount offer

Tongjitang first-quarter net revenue up 25.6% to $16.6 million

Physical fitness reduces metabolic risk in college students

Research examines relationship between body-image distortion and weight-loss behaviors

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Exercise News and Research

Latest Exercise News and Research

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Unlocking live single-cell functional insights

Newsletters you may be interested in